Common Equity: The sum of all common equity items.
Tarsus Pharmaceuticals, Inc. (TARS) had Common Equity of $346.73M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$173.91M |
|
$-18.55M |
|
$12.11M |
|
$161.80M |
|
$193.82M |
|
$-19.91M |
|
$4.07M |
|
$-15.84M |
|
$-15.84M |
|
$-18.55M |
|
$-18.55M |
|
$-18.55M |
|
$-18.55M |
|
$-19.91M |
|
$-19.50M |
|
43.39M |
|
43.39M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$561.99M |
|
$20.49M |
|
$49.15M |
|
$611.14M |
|
$175.75M |
|
$72.76M |
|
$88.66M |
|
$264.41M |
|
|
Common Equity |
$346.73M |
$339.85M |
|
$346.73M |
|
43.27M |
|
| Cash Flow Statement Financials | |
$36.57M |
|
$-20.68M |
|
$4.51M |
|
$186.20M |
|
$206.60M |
|
$20.39M |
|
$25.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.20 |
|
-- |
|
-- |
|
0.17 |
|
0.21 |
|
93.03% |
|
-11.45% |
|
-11.45% |
|
-- |
|
-9.11% |
|
-10.67% |
|
$26.68M |
|
-- |
|
-- |
|
-- |
|
0.28 |
|
2.77 |
|
1.77 |
|
50.88 |
|
-5.35% |
|
-5.46% |
|
-3.04% |
|
-4.42% |
|
$8.01 |
|
$0.61 |
|
$0.84 |
|